Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Eli Lilly announced Wednesday it will invest another $4.5 billion into a new facility at the states controversial LEAP ...
Oct 2 (Reuters) - The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback